Journal of Clinical Medicine · Nov 16, 2026
Prevalence, Clinical Profile, and Management of Patients with Left Ventricular Systolic Dysfunction: The PROACTIVE-HF Score
By De Rueda Panadero C, González Martín S, Ducay Rico J et al.
Background/Objectives: To evaluate the prevalence, clinical profile, management, and 1-year outcomes of patients with left ventricular systolic dysfunction (LVSD) identified through routine transthoracic echocardiography (TTE) in a tertiary care setting, and to develop a tool that stratifies the risk of death or hospitalization and thereby helps identify patients who require referral to specialized heart failure (HF) care. Methods: Single-center, retrospective cohort study of consecutive adults with a left ventricular ejection fraction (LVEF) ≤ 40% identified by TTE in 2021. According to the follow-up received during the subsequent year, patients were classified into three groups: “HF Clinic” (56.9%), “General Cardiologists” (23.0%), or “Non-cardiologists” (20.1%). The primary outcome was the composite rate of all-cause death or hospitalization at 12 months. A multivariable logistic regression model was used to derive the PROACTIVE-HF risk score, internally validated by bootstrap. Landmark analyses at 30 and 90 days and a time-dependent Cox model were performed to address potential immortal time bias related to follow-up classification. Results: Of 12,205 subjects who underwent TTE, 506 had LVSD (4.15% of patients undergoing TTE); 483 formed the final cohort. Patients followed by Non-cardiologists were older, more comorbid, and received less guideline-directed medical therapy. The primary endpoint occurred in 40.4% of the global cohort and was markedly higher in the Non-cardiologists group compared with General Cardiologists and HF Clinic groups (72.2% vs. 34.2% vs. 31.6%, p < 0.001), mainly driven by higher all-cause death (57.7% vs. 10.8% vs. 7.6%, p < 0.001). Most deaths in the Non-cardiologists group were non-cardiovascular. In the time-dependent model, cardiology follow-up was associated with a lower hazard of the primary endpoint (hazard ratio 0.42, 95% confidence interval 0.30–0.59). The PROACTIVE-HF score (age, body mass index [BMI], diabetes mellitus, use of sodium–glucose cotransporter-2 [SGLT2] inhibitors, loop diuretics, renin–angiotensin–aldosterone system [RAAS] inhibitors, and TTE referral by non-cardiologists) discriminated low- (16.8%), intermediate- (37.9%), and high-risk (66.5%) groups for the 1-year primary endpoint (C-statistic 0.75; 0.73 after bootstrap optimism correction). Conclusions: A significant gap exists in the referral pathways for patients with LVSD identified by routine TTE. Patients without cardiology follow-up had worse 1-year outcomes; this association persisted after accounting for immortal time bias, but likely reflects, in part, frailty and competing non-cardiac illness. The PROACTIVE-HF score offers a pragmatic triage strategy that may facilitate more equitable access to specialized HF care, pending external validation.